ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

16 Tips from 16 Years Sick

Fibromyalgia Fare Fit for All Seasons

New Study Shows Artificial Sweeteners Lead to Diabetes

Essential Oils — An Effective and Healthy Option to Treat Headaches

Higher vitamin D levels associated with less severe disease in NAFLD patients

Krill Oil: Make This Omega-3 Supplement Part of Your Health Regimen

How zinc helps fight esophageal cancer

Everything You Need to Know About Black Cohosh

Low vitamin D levels predict ED in diabetics

The Cellular Enzyme That Promotes Longevity And Reduces Fat Storage

 
Print Page
Email Article

Merck Denies Vioxx Linked to Eleven Deaths

  [ 10 votes ]   [ Discuss This Article ]
By Deborah Cooper • www.ProHealth.com • September 19, 2000


Eleven patients using Vioxx have died in Britain according to a UK drug regulatory body, but the drug manufacturer Merck & Co. deny its arthritis drug was linked to the mortalities.

In addition to the deaths the UK’s regulatory bodies, the Medicines Control Agency and the Committee on the Safety of Medicines has received 1,120 reports of adverse effects to rofecoxib, the generic name for Vioxx.

According to the report published in the agency's September newsletter Current Problems, “Gastrointestinal (GI) adverse reactions account for almost half (554) of the reports, of which the majority were nausea, dyspepsia, diarrhea and abdominal pain. However, there have been 68 reports of upper GI perforations, ulcerations and bleeds (PUBs). Forty-four of the patients with PUBs recovered, although five had a fatal outcome.”

It is these five fatalities, along with six other deaths in people with possible cardiac failure and among people with a high risk factor for cardiovascular disease, that has raised the alarm for prescribers and consumers alike.

The other deaths mentioned in the report were part of a total of 192 incidences of suspected cardiovascular reactions, including 15 reports of cardiac failure, 101 reports of edema and 19 reports of palpitations.

Merck & Co., the US drug giant, said that none of the deaths was linked to the medicine. A spokeswoman for the company, Mary Elizabeth Basaman said “There is not a cause and effect. They’re not attributing anything to a specific drug.” Another Merck official, Eve Slater, added, “The report…is no cause for concern.”

The drug maker also pointed out that eleven deaths in a large aging population should not be considered remarkable.

However, the regulatory agency's report concluded with a cautious note. “As with all new drugs, the safety of refocoxib remains under close review.”

An estimated 557,100 prescriptions for Vioxx were dispensed in Britain up to the end of May 2000. The rate of reported adverse reactions is approximately one per 500 prescriptions.

Vioxx is approved in the US and UK as a treatment for osteoarthritis, the most common form of arthritis affecting more than 16 million Americans. Its competitor is another drug also in the same class of non steroidal anti-inflammatory drugs, the Cox-2 inhibitor Celebrex, manufactured by Pharmacia Corp. Last year, Celebrex reached $1.5 billion in sales and Vioxx, launched four months later, garnered $472 million. Both drugs are considered safer and easier to handle than some older arthritis medications such as aspirin.

Rofecoxib (Vioxx) does come with warnings that it is contraindicated in patients with active peptic ulceration or GI bleeding, as well as for patients with severe congestive heart failure. Caution is also urged for users who have a history of cardiac failure, left ventricular dysfunction or hypertension, and in patients with pre-existing edema for any other reason.



Post a Comment

Featured Products From the ProHealth Store
Ultra EPA  - Fish Oil Vitamin D3 Extreme™ Mitochondria Ignite™ with NT Factor®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Block food Cravings At Their Molecular Root Block food Cravings At Their Molecular Root
How to Jump-start and Sustain Energy Production in CFS How to Jump-start and Sustain Energy Production in CFS
The Curcumin Revolution: 'Golden' Ticket to Better Health The Curcumin Revolution: 'Golden' Ticket to Better Health
Soothe, Heal and Regulate Your Digestive System with Nutrient-Rich Aloe Vera Soothe, Heal and Regulate Your Digestive System with Nutrient-Rich Aloe Vera
Can Autoimmune Conditions be Reversed? Researchers Make a Surprising Discovery Can Autoimmune Conditions be Reversed? Researchers Make a Surprising Discovery

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map